Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.56% | 6.28% | -16.12% | -34.06% | -39.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.56% | 6.28% | -16.12% | -34.06% | -39.99% |
| Cost of Revenue | 4.16% | 18.21% | -18.80% | -27.02% | -34.22% |
| Gross Profit | 16.00% | 0.84% | -14.64% | -37.61% | -42.99% |
| SG&A Expenses | 34.40% | 16.60% | 9.11% | -12.29% | -50.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.71% | 16.75% | 5.14% | -14.26% | -49.04% |
| Operating Income | -39.95% | -22.32% | -19.07% | 0.96% | 52.51% |
| Income Before Tax | -37.90% | -16.06% | -84.38% | 7.74% | -162.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.90% | -16.06% | -84.38% | 7.74% | -162.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.90% | -16.06% | -84.38% | 7.74% | -162.34% |
| EBIT | -39.95% | -22.32% | -19.07% | 0.96% | 52.51% |
| EBITDA | -40.02% | -22.89% | -20.31% | -0.24% | 52.34% |
| EPS Basic | -200.00% | -100.00% | -100.00% | 0.00% | -133.33% |
| Normalized Basic EPS | -- | -- | -- | -- | -100.00% |
| EPS Diluted | -200.00% | -100.00% | -100.00% | 0.00% | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -100.00% |
| Average Basic Shares Outstanding | 1.29% | 0.91% | 0.83% | 0.87% | 0.57% |
| Average Diluted Shares Outstanding | 99.34% | 99.11% | 0.83% | 0.87% | -43.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |